OTCM
EBRCZ
Market cap79mUSD
Oct 15, Last price
0.11USD
Name
EBR Systems Inc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
EBR Systems, Inc. focuses on developing internal medical devices that utilize wireless technology for tissue stimulation. A key offering is their WiSE cardiac resynchronization therapy (CRT) system, which leverages proprietary cable-free technology to deliver electrical pacing directly into the heart's left ventricle. This innovative approach aims to address and eliminate the typical difficulties associated with traditional wired leads, such as challenging insertion, unintended nerve activation, device displacement, complex removal procedures, and the need for frequent repositioning. The company was established in 2003 and operates from its headquarters in Sunnyvale, California.
Key people
Executive Chairman of the Board · since 2019
John Mccutcheon
President, Chief Executive Officer, Executive Director · since 2019
Gary Doherty
Chief Financial Officer · since 2023
Michael Hendrickson
Chief Operating Officer · since 2021
Andrew Shute
Senior Vice President - Global Field Operations · since 2015
N. Parker Willis
Chief Technology Officer · since 2011
Pharoah Garma
Chief Regulatory Officer · since 2024
Spencer Kubo
Chief Medical Officer · since 2018
Kobe Li
Company Secretary, Australia · since 2025
Erik Strandberg
Chief Commercial Officer · since 2024
John Sellers
Company Secretary - Unites States · since 2021
Trevor Moody
Non-Executive Director · since 2017
Christopher Nave
Non-Executive Director · since 2017
Karen Drexler
Non-Executive Independent Director · since 2021
Bronwyn Evans
Non-Executive Independent Director · since 2021
David Steinhaus
Non-Executive Independent Director · since 2021
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||||
Revenues | |||||||
Cost of revenue | |||||||
Unusual Expense (Income) | |||||||
NOPBT | |||||||
NOPBT Margin | |||||||
Operating Taxes | |||||||
Tax Rate | |||||||
NOPAT | |||||||
Net income | |||||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | |||||||
BB yield | |||||||
| Debt | |||||||
Debt current | |||||||
Long-term debt | |||||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | |||||||
| Cash flow | |||||||
Cash from operating activities | |||||||
CAPEX | |||||||
Cash from investing activities | |||||||
Cash from financing activities | |||||||
FCF | |||||||
| Balance | |||||||
Cash | |||||||
Long term investments | |||||||
Excess cash | |||||||
Stockholders' equity | |||||||
Invested Capital | |||||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | |||||||
Price | |||||||
Market cap | |||||||
EV | |||||||
EBITDA | |||||||
EV/EBITDA | |||||||
Interest | |||||||
Interest/NOPBT | |||||||